BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer
Globenewswire· 2025-08-13 11:30
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce its acceptance into Memorial Sloan Kettering Cancer Center’s (MSK’s) Therapeutics Accelerator 2025 Cohort program. This project aims to accelerate the clinical development of Bria-OTS+, BriaCell’s next genera ...
Nexxen Reports Second Quarter 2025 Financial Results
Globenewswire· 2025-08-13 11:30
Generated record Q2 Contribution ex-TAC, programmatic revenue and CTV revenue Increased Adjusted EBITDA Margin to 34% of Contribution ex-TAC from 32% in Q2 2024 Renewed and expanded strategic partnership with VIDAA in Q3 2025 through at least the end of 2029, and increasing investment in VIDAA by $35 million to accelerate their North American CTV and data footprint NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Nexxen International Ltd. (NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, flexible advertising ...
MasterCraft Boat Holdings, Inc. to Webcast Fiscal Fourth Quarter and Full Year 2025 Earnings Conference Call Wednesday, August 27, 2025
Globenewswire· 2025-08-13 11:30
Live webcast at 8:30 a.m. EDTVONORE, Tenn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- MasterCraft Boat Holdings, Inc. (NASDAQ: MCFT) (the “Company”) will host a live webcast of its fiscal fourth quarter and full year 2025 earnings conference call on Wednesday, August 27, 2025, at 8:30 a.m. EDT. Brad Nelson, Chief Executive Officer and Scott Kent, Chief Financial Officer, will discuss the Company’s financial results. The Company will issue a pre-market earnings release prior to the call on August 27, 2025. Participa ...
Humanoid Global Announces Uplisting to the OTCQB Market
GlobeNewswire News Room· 2025-08-13 11:30
Vancouver, BC, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Humanoid Global Holdings Corp. (“Humanoid Global” or the “Company”) (CSE:ROBO, FWB:0XM1, OTCQB:RBOHF), a publicly traded investment issuer focused on building and accelerating a portfolio of pioneering companies in the humanoid robotics and embodied AI sector, is pleased to announce that it has been approved to have its common shares uplisted from the OTC Pink Sheets to the OTCQB Market (“OTCQB”). The Company’s common stock began trading today on the OTCQB un ...
BrainsWay Reports Second Quarter 2025 Financial Results and Operational Highlights
Globenewswire· 2025-08-13 11:30
Achieved record quarterly revenue of $12.6 million in Q2 2025, an increase of 26% compared to Q2 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.5 million, Raised full-year 2025 Revenue and EBITDA guidance Remaining performance obligations increased by 25% YOY to $62 million Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advance ...
Base Carbon Reports Second-Quarter 2025 Operating and Financial Results
Globenewswire· 2025-08-13 11:30
TORONTO, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Base Carbon Inc. (Cboe CA: BCBN) (OTCQX: BCBNF) with operations through its wholly-owned subsidiary, Base Carbon Capital Partners Corp. (“BCCPC”, together, with affiliates, “Base Carbon”, or the “Company”), is pleased to announce its second-quarter 2025 consolidated financial results and operational highlights. The Company will host an investor town hall in September, with details to follow over the coming weeks. All financial references are denominated in U.S. dol ...
Nasus Pharma Announces Pricing of $10 Million Initial Public Offering
GlobeNewswire News Room· 2025-08-13 11:30
TEL AVIV, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the pricing of its initial public offering of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10 million, prior to deducting underwriting discounts, co ...
Lululemon: The Situation Is Better Than You Think
Seeking Alpha· 2025-08-13 11:26
Over the last five years, the SPDR S&P Retail ETF ( XRT ) has returned a modest 60%. Conversely, lululemon (NASDAQ: LULU ) has dropped more than 42% during this same period. How has the broad consumerTQP Research is run by a Certified Public Accountant (CPA) with several years of experience in structured finance and banking.TQP Research follows a value-oriented investment approach by identifying businesses that meet the criteria for long-term success taught by Warren Buffett, Charlie Munger, and Walter Schl ...
Gauzy Ltd. Announces Second Quarter 2025 Results
Globenewswire· 2025-08-13 11:23
Record Backlog Purchase Orders of $42.9 Million at Quarter End Highly Anticipated New Product Lines Announced; Includes Commercial Aircraft Cabin Shading, ADAS Smart Vision for Buses, and Pre-Fabricated Stacks for Smart Glass New Strategic Customers Secured in Architecture, Aeronautics and Safety Tech Closed on $15 Million of Debt Financing with Mizrahi Bank, Israel’s Third Largest Bank, Including $5 Million in July Reaffirms 2025 Guidance TEL-AVIV, Israel and NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Gau ...
Denison Announces Pricing of Upsized US$300 Million Convertible Senior Notes Offering
Prnewswire· 2025-08-13 11:18
TORONTO, Aug. 13, 2025 /PRNewswire/ - Denison Mines Corp. (TSX: DML)(NYSE AMERICAN: DNN) ("Denison" or the "Company") announces that, on August 12, 2025, it upsized and priced its previously announced offering of convertible senior unsecured notes due 2031 (the "Notes") for an aggregate principal amount of US$300 million (the "Offering"). The Company has granted the initial purchasers of the Notes an option for a period of 13 days, beginning on, and including the date on which the Notes are first issued, to ...